Global Search | Novartis

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 2775 results

Press release / Sep 25, 2015

Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval

Positive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart failure trial which…
Press release / Sep 27, 2015

Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET

In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional…
Pulse Update / Sep 02, 2021

Novartis receives FDA fast track designation for LNA043 in osteoarthritis of the knee
Pulse Update / May 25, 2021

Novartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes
Pulse Update / Jul 27, 2021

Novartis receives FDA Orphan Drug Designation for NIS793 in pancreatic cancer
Pulse Update / Aug 25, 2021

FDA accelerates review of Novartis STAMP inhibitor asciminib (ABL001) for patients with chronic myeloid leukemia (CML)
Pulse Update / Jul 06, 2021

Novartis announces Complete Response Resubmission for inclisiran New Drug Application
Pulse Update / Sep 03, 2021

Novartis announces discontinuation of CIRRUS-1 study of CFZ533 (iscalimab) in kidney transplant patients
Pulse Update / Jun 10, 2021

Novartis Entresto® indicated for treatment of hypertension in China
Story / Mar 07, 2019

Enabling 130,000 employees to grow in an organization committed to continuous learning

People and Culture

Our Chief Learning Officer, Simon Brown, talks about our ongoing efforts to build new capabilities by investing in our own people.